SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
SAN RAMON, Calif., Feb. 02, 2016 -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the BIO CEO & Investor Conference. The presentation will take place on Monday, February 8, 2016 at 11:30 a.m. ET at the Waldorf Astoria Hotel in New York, NY.
The presentation will be webcast and available on the Investors section of the Company's website at http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancer and in a Phase 1b given sequentially with GALE-302. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact: Remy Bernarda SVP, Investor Relations & Corporate Communications (925) 498-7709 [email protected]
